Icon's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. Icon has historically maintained a fairly conservative balance sheet, and it ended ...
All figures are in United States dollars unless otherwise stated. This news release contains forward-looking information that ...
In the fourth quarter of 2024, BB Biotech shares posted a total return of -2.7% in CHF and -3.5% in EUR. NAV performance improved, rising by 2.7% in CHF and 2.8% in EUR, though it declined by 4.3% in ...
With extreme weather events increasing due to climate change, experts about from the unpreparedness of the electricity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback